GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
September 30, 2024 08:30 ET
|
GRI Bio, Inc.
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE...
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
September 26, 2024 08:00 ET
|
GRI Bio, Inc.
MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment...
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
September 25, 2024 08:45 ET
|
GRI Bio, Inc.
Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
GRI Bio Participates in Virtual Investor KOL Connect Segment
September 18, 2024 09:00 ET
|
GRI Bio, Inc.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey,...
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio to Present at the 2024 European Respiratory Congress
September 04, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
July 15, 2024 09:05 ET
|
GRI Bio, Inc.
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
July 11, 2024 09:20 ET
|
GRI Bio, Inc.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...